The present invention relates to ocular compositions for the
controlled release of a therapeutic agent. The ocular composition comprises at least 20% w / w of a therapeutic agent; 5 to 75% w / w of a photopolymerizable composition selected from the group consisting of fragments or monomers of polyalkylene glycol mono-
acrylate, polyalkylene
glycol diacrylate, polyalkylene
glycol methacrylate and polyalkylene
glycol dimethacrylate, and mixtures, copolymers, and block copolymers thereof; 0.1 to 40% w / w of a
biodegradable polymer selected from the group consisting of
lactide / glycolide
copolymer (including poly(
lactide-co-glycolide) (
PLGA)), poly (L-
lactide) (PLA),
polyhydroxyalkanoates, including
polyhydroxybutyrate, polyglycolic acid (PGA),
polycaprolactone (PCL), poly (DL-lactide) (PDL), poly (D-lactide), lactide /
caprolactone copolymer, poly-L-lactide-co-
caprolactone (PLC) and mixtures, copolymers, and block copolymers thereof; and a
photoinitiator.